John Doll – Commissioner for Patents
February 1, 2006
Agency developing new strategic plan
- Part of budget process
- Planning for at least six-year period
- Anticipate, plan for USPTO role in changing environment
- Seeking broad perspective:
- input from interested persons, stakeholders, including
- Industries (large and small business), inventors, employees, practitioners
Please send ideas/thoughts/suggestions to StrategicPlanning1@uspto.gov
EFS-Web: Newly Improved On-Line Solution For Patent Filers
- EFS-Web will allow patent filers, anywhere, anytime, to submit patent applications, related documents, and pay fees online.
- Currently in Beta-testing
- Rollout to all comers expected mid-March 2006
EFS-Web Advantages to Patent Filers
- File applications and related documents using existing technologies and workflows.
- Submit applications and related documents by simply attaching PDF files.
- Staff may transmit filing on behalf of patent practitioners.
- Verifies and validates files before submission.
- Automatic electronic acknowledgement receipt confirming submission.
- Rapid access to PAIR to view submission and status and to confirm documents safely and accurately received.
EFS-Web Schedule and Support
- Electronic Business Center (EBC) support available from 6 a.m. to 12 Midnight Eastern Monday-Friday
- EBC Contact Numbers:
- 1-866-217-9197
- 571-272-4100
- 571-273-0177 (fax)
- E-mail: ebc@uspto.gov
- Online Training Available
Questions
- EFS Web receipt time or filing date is based on USPTO East Coast time as defined by Statute.
- What can be filed in EFS-Web?
- New Applications: Utility, Provisional, Design with Color Drawings, 371 National Stage
- Follow-on submission associated with an Application
- Over 80 document descriptions - Amendments, Petitions, Board of Appeals Documents, Non-Patent Literature, Foreign References Cited etc etc
- Numerous Fees
- Filing Fees
- Extensions of Time
- Petition Fees
Newly Proposed 12 Month Accelerated Examination Procedure
- Goal: A final disposition of an application can be reached within 12 months from the filing date of the application.
- Final disposition: allowance, abandonment, or appeal.
- An OG notice will soon be published.
- Revising the requirements and procedures for petitions to make special under the accelerated examination program, and 37 CFR 1.102(c)(2), set forth in MPEP 708.02.
Application Filingsand Examiner Production
UPR Applications Filed
[D]
- FY 05 plan 375,080 (5.5% above FY 04)
- FY 05 actual 384,228 (8.1% above FY04)
- 2.6% over plan
Production
|
FY 04 |
FY 05 Target |
FY 05 |
UPR1 FAOM2 |
288,315 |
297,614 |
297,287 |
UPR Disposals3 |
287,188 |
295,456 |
279,345 |
UPR Production Units4 |
287,752 |
296,535 |
288,316 |
PCT Production Units5 |
16,882 |
22,916 |
15,147 |
1 “UPR” = Utility, Plant, and Reissue Applications.
2 “FAOM” = First Action on the Merits – first action count by an examiner after the filing of an application (does not include restrictions or other miscellaneous actions).
3 “Disposal” = An examiner allowance, abandonment, or disposals following a board decision.
4 “Production Unit” = First action count plus disposal count divided by 2.
5 “PCT” = Patent Cooperation Treaty. PCT applications are processed differently and tracked separately from US National stage applications. For FY 05, 15,147 PU’s is 35,389 processed applications.
PENDENCY. . . vs the Backlog
First Action Pendency by Art Areas
High Pendency Art Areas |
Pendency1 (months) |
Low Pendency Art Areas |
Pendency1 (months) |
1640 – Immunology, Receptor/ Ligands, Cytokines, Recombinant Hormones, and Molecular Biology |
27.7 |
1620 – Heterocyclic Compounds and Uses |
16.9 |
1743 – Analytic Chemistry & Wave Energy |
30.8 |
1752 – Radiation Imagery |
12.1 |
2123 – Simulation and Modeling, Emulation of Computer Components |
39.7 |
2125 – Manufacturing Control Systems and Chemical/ Mechanical/Electrical Control |
20.0 |
2617 – Interactive Video Distribution |
50.4 |
2651 – Dynamic Information Storage & Retrieval |
16.1 |
2836 – Control Circuits |
24.3 |
2651 – Dynamic Information Storage & Retrieval |
8.8 |
3628 – Finance & Banking, Accounting |
52.1 |
3612 – Land Vehicles |
12.0 |
3731 – Surgery: Cutting, Clamping, Suturing |
30.9 |
3723 – Tools & Metal Working |
10.9 |
1 “Average 1st action pendency” is the average age from filing to first action for a newly filed application, completed during October-December 2005.
Inventory by Art Examples
High Inventory Art Areas |
Months of Inventory* |
Low Inventory Art Areas |
Months of Inventory* |
1614, 1615, and 1617 – Drugs, Bio-affecting and Body Treatment |
38-51 |
1620 – Organic Chemistry |
15 |
1753 – Radiation Imagery |
34 |
1734 – Adhesive Bonding and Coating Apparatus |
10 |
2127 – Computer Task Management |
46 |
2125 – Manufacturing Control Systems and Chemical/ Mechanical/Electrical Control |
10 |
2611 – Interactive Video Distribution |
114 |
2651, 2653 – Information Storage and Retrieval |
12 |
2836 – Control Circuits |
22 |
2831 – Electrical Conductors |
8 |
3620 – Business Methods |
22-136 |
3651 – Conveying |
12 |
3731 and 3737 – Medical Instruments, Diagnostic Equipment |
38-47 |
3742 – Thermal and Combustion Technology |
8 |
*The number of months it would take to reach a first action on the merits (e.g., an action addressing patentability issues) on a new application filed in July 2005 at today’s production rate. Today’s production rate means that there are no changes in production due to hiring, attrition, changes to examination processing or examination efficiencies, and that applications are taken up in the order of filing in the given art unit/area. Of course, USPTO is taking aggressive steps to ensure changes that will significantly lower the inventory rates in high-inventory art areas.
TC Application Inventory
|
1600 |
1700 |
2100 |
2600 |
2800 |
3600 |
3700 |
Total* |
Design |
New Applications1 9/30/2004 |
55,402 |
63,923 |
71,778 |
97,380 |
77,651 |
56,738 |
65,005 |
508,878 |
18,451 |
New Applications 1 9/30/2005 |
62,644 |
72,697 |
76,529 |
115,585 |
94,425 |
70,354 |
83,225 |
586,580 |
24,534 |
Overall Pending Applications2 9/30/2004 |
95,006 |
105,447 |
102,440 |
138,822 |
137,458 |
101,097 |
108,039 |
809,323 |
27,599 |
Overall Pending Applications2 9/30/2005 |
107,647 |
120,767 |
117,728 |
167,721 |
159,687 |
117,045 |
130,168 |
932,300 |
38,104 |
1 “New Application inventory” is the number of new applications designated or assigned to a technology center awaiting a first action.
2 “Overall Pending Application inventory” is the total number of applications designated or assigned to a technology center in an active status. Includes new applications; rejected awaiting response; amended; under appeal or interference; suspended; reexams and allowed applications awaiting grant publication.
*Total inventory includes applications not assigned to a particular TC, awaiting processing either pre- or post-examination.
Patent Quality (Shared Responsibility)
Quality of Products – FY 05
Fiscal Year 2005
|
FY 04 |
1600 |
1700 |
2100 |
2600 |
2800 |
3600 |
3700 |
Design |
FY 05 |
FY 05 Target |
Patent In-Process Examination Compliance Rate 1* |
82.0% |
81.7% |
82.9% |
88.1% |
84.7% |
90.9% |
84.4% |
86.6% |
94.3% |
86.2% |
84.0% |
Patent Allowance Error Rate2* |
5.32% |
4.88% |
6.46% |
3.56% |
2.25% |
4.43% |
4.94% |
6.43% |
1.6% |
4.55% |
4.0% |
*Compliance and error rates as measured by OPQA.
1Compliance is the percent of office actions reviewed and found to be free of any in-process examination deficiency (an error that has significant adverse impact on patent prosecution).
2Patent allowance error rate is the percent of allowed applications reviewed having at least one claim which is considered unpatentable on a basis for which a court would hold a patent invalid. “Allowance” occurs before a patent is issued, so these errors are caught before any patent is actually granted.
Re-Work
Technology Centers Rework* Statistics
|
FY 2002 |
FY 2003 |
FY 2004 |
FY 2005 |
TC Summary |
% FAOM Rework |
% FAOM Rework |
% FAOM Rework |
% FAOM Rework |
1600 |
36.4% |
39.7% |
40.3% |
42.4% |
1700 |
25.2% |
26.9% |
27.1% |
28.0% |
2100 |
23.9% |
24.0% |
24.6% |
28.2% |
2600 |
24.8% |
24.1% |
24.3% |
25.4% |
2800 |
19.1% |
22.0% |
24.9% |
24.1% |
3600 |
17.7% |
21.2% |
23.1% |
28.5% |
3700 |
22.2% |
25.1% |
24.0% |
28.1% |
UPR |
23.2% |
25.3% |
26.1% |
28.3% |
* Rework first actions are those actions that are in a Continuing (CONs and CIPs), RCE, CPA or 129(a) applications (excludes Divisionals).
Hiring and Retention
Hires and Attritions
|
1600 |
1700 |
2100 |
2600 |
2800 |
3600 |
3700 |
Corps |
Design |
FY 04 Hires |
75 |
35 |
115 |
116 |
31 |
26 |
45 |
443 |
15 |
FY 04 Attritions |
30 |
26 |
58 |
82 |
58 |
43 |
39 |
336 |
4 |
FY 05 BOY Examiner Staff |
417 |
440 |
563 |
658 |
742 |
422 |
439 |
3681 |
72 |
FY 05 Hiring |
101 |
58 |
225 |
169 |
184 |
91 |
131 |
959 |
19 |
FY 05 Attrits |
42 |
39 |
93 |
92 |
54 |
55 |
50 |
425 |
10 |
FY 06 Hiring Goal |
30 |
35 |
256 |
256 |
178 |
100 |
100 |
1000 |
20 |
FY 06 hires (1/25/06) |
30 |
19 |
75 |
62 |
40 |
22 |
21 |
269 |
0 |
FY05 Hires as a Percent of Examiner Staffing in the TC |
24% |
13% |
40% |
26% |
25% |
22% |
30% |
26% |
26% |
Markush Practice
- A cell adhesion protein of formula (1),
A-(B)-(C)-(D)n-E
or a pharmaceutically acceptable derivative thereof , wherein . . .
A composition molecules for use as tags or tag complements wherein in each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a following groups of sequences:
1 |
4 |
6 |
8 |
1 |
3 |
2 |
4 |
5 |
5 |
2 |
3 |
1 |
8 |
1 |
2 |
3 |
4 |
1 |
1 |
9 |
2 |
6 |
9 |
1 |
2 |
4 |
3 |
9 |
6 |
9 |
8 |
9 |
8 |
10 |
9 |
9 |
1 |
2 |
3 |
8 |
10 |
8 |
8 |
7 |
4 |
3 |
1 |
1 |
1 |
1 |
1 |
1 |
2 |
2 |
1 |
3 |
3 |
2 |
2 |
3 |
1 |
2 |
2 |
3 |
2 |
4 |
1 |
4 |
4 |
4 |
2 |
1 |
2 |
3 |
3 |
1 |
1 |
1 |
3 |
2 |
2 |
1 |
4 |
3 |
3 |
3 |
3 |
3 |
4 |
4 |
3 |
1 |
1 |
4 |
4 |
3 |
4 |
1 |
1 |
3 |
3 |
3 |
6 |
6 |
6 |
3 |
5 |
6 |
6 |
1 |
1 |
6 |
5 |
7 |
6 |
7 |
7 |
7 |
5 |
8 |
7 |
5 |
5 |
8 |
8 |
2 |
1 |
7 |
7 |
1 |
1 |
2 |
3 |
2 |
3 |
1 |
3 |
2 |
6 |
5 |
6 |
1 |
6 |
4 |
8 |
1 |
1 |
3 |
8 |
5 |
3 |
1 |
1 |
6 |
3 |
5 |
6 |
8 |
8 |
6 |
6 |
8 |
3 |
6 |
5 |
7 |
3 |
1 |
2 |
3 |
1 |
4 |
6 |
1 |
5 |
7 |
5 |
4 |
3 |
2 |
1 |
6 |
7 |
3 |
6 |
2 |
6 |
1 |
3 |
3 |
1 |
2 |
7 |
6 |
8 |
3 |
1 |
3 |
4 |
3 |
1 |
2 |
5 |
3 |
5 |
6 |
1 |
2 |
7 |
3 |
6 |
1 |
7 |
2 |
7 |
4 |
6 |
3 |
5 |
1 |
7 |
5 |
4 |
6 |
3 |
8 |
6 |
6 |
8 |
2 |
3 |
7 |
1 |
7 |
1 |
7 |
8 |
6 |
3 |
7 |
3 |
4 |
1 |
6 |
8 |
4 |
7 |
8 |
1 |
2 |
4 |
3 |
6 |
5 |
2 |
6 |
3 |
1 |
4 |
1 |
4 |
6 |
1 |
3 |
3 |
1 |
4 |
8 |
1 |
8 |
3 |
3 |
5 |
3 |
8 |
1 |
3 |
6 |
6 |
3 |
7 |
7 |
3 |
8 |
6 |
4 |
7 |
3 |
1 |
3 |
7 |
8 |
6 |
10 |
9 |
5 |
5 |
10 |
10 |
7 |
10 |
10 |
10 |
7 |
10 |
9 |
9 |
7 |
7 |
10 |
9 |
9 |
3 |
10 |
3 |
10 |
3 |
9 |
6 |
3 |
4 |
10 |
6 |
10 |
4 |
10 |
3 |
9 |
4 |
3 |
9 |
3 |
10 |
4 |
9 |
9 |
10 |
5 |
9 |
4 |
8 |
3 |
9 |
4 |
9 |
10 |
7 |
3 |
5 |
9 |
4 |
10 |
8 |
4 |
10 |
5 |
4 |
9 |
3 |
5 |
3 |
3 |
9 |
8 |
10 |
5 |
8 |
6 |
9 |
7 |
10 |
4 |
5 |
10 |
9 |
6 |
4 |
4 |
9 |
8 |
10 |
8 |
3 |
7 |
7 |
9 |
10 |
5 |
3 |
8 |
8 |
9 |
3 |
9 |
10 |
8 |
10 |
2 |
9 |
5 |
9 |
9 |
6 |
2 |
2 |
7 |
10 |
9 |
7 |
5 |
3 |
10 |
6 |
10 |
3 |
6 |
8 |
9 |
2 |
10 |
9 |
3 |
2 |
7 |
3 |
8 |
9 |
10 |
3 |
6 |
2 |
3 |
2 |
5 |
10 |
8 |
9 |
8 |
2 |
3 |
10 |
2 |
9 |
6 |
3 |
9 |
8 |
2 |
10 |
3 |
7 |
3 |
9 |
9 |
10 |
9 |
10 |
1 |
1 |
9 |
4 |
10 |
1 |
9 |
1 |
4 |
1 |
7 |
1 |
10 |
9 |
8 |
1 |
9 |
1 |
10 |
1 |
10 |
6 |
9 |
6 |
9 |
1 |
3 |
10 |
3 |
10 |
8 |
8 |
9 |
1 |
3 |
8 |
1 |
9 |
10 |
3 |
9 |
10 |
1 |
3 |
6 |
9 |
1 |
9 |
1 |
10 |
3 |
1 |
1 |
4 |
9 |
6 |
8 |
10 |
3 |
3 |
9 |
6 |
1 |
10 |
5 |
3 |
1 |
6 |
9 |
10 |
6 |
1 |
8 |
10 |
9 |
6 |
5 |
9 |
9 |
4 |
10 |
3 |
2 |
10 |
9 |
1 |
9 |
5 |
10 |
10 |
7 |
2 |
1 |
9 |
10 |
9 |
9 |
1 |
8 |
2 |
1 |
8 |
6 |
8 |
9 |
10 |
1 |
9 |
1 |
3 |
8 |
10 |
9 |
8 |
9 |
10 |
1 |
2 |
1 |
10 |
8 |
9 |
9 |
2 |
1 |
9 |
6 |
7 |
2 |
9 |
4 |
3 |
9 |
3 |
5 |
1 |
5 |
11 |
10 |
14 |
12 |
1 |
7 |
12 |
4 |
13 |
3 |
2 |
5 |
5 |
4 |
4 |
12 |
9 |
2 |
13 |
13 |
11 |
13 |
13 |
10 |
2 |
5 |
4 |
12 |
7 |
11 |
7 |
4 |
11 |
6 |
4 |
12 |
12 |
1 |
9 |
11 |
11 |
12 |
9 |
4 |
14 |
12 |
6 |
12 |
7 |
13 |
2 |
9 |
11 |
9 |
11 |
3 |
4 |
1 |
3 |
10 |
5 |
12 |
11 |
4 |
4 |
4 |
13 |
8 |
13 |
1 |
5 |
9 |
13 |
10 |
11 |
11 |
6 |
10 |
14 |
14 |
10 |
1 |
3 |
2 |
14 |
1 |
10 |
4 |
5 |
10 |
12 |
12 |
8 |
11 |
10 |
9 |
11 |
2 |
12 |
8 |
11 |
2 |
8 |
5 |
2 |
12 |
14 |
1 |
8 |
13 |
3 |
7 |
8 |
9 |
4 |
7 |
5 |
4 |
2 |
13 |
2 |
12 |
7 |
1 |
12 |
11 |
10 |
9 |
7 |
5 |
11 |
8 |
12 |
2 |
2 |
12 |
7 |
5 |
2 |
14 |
3 |
4 |
18 |
1 |
8 |
8 |
1 |
5 |
9 |
14 |
5 |
11 |
10 |
13 |
3 |
14 |
1 |
4 |
13 |
2 |
4 |
4 |
4 |
5 |
11 |
3 |
10 |
10 |
9 |
2 |
3 |
3 |
11 |
11 |
4 |
8 |
14 |
3 |
4 |
5 |
1 |
14 |
8 |
11 |
2 |
14 |
3 |
11 |
6 |
12 |
5 |
13 |
4 |
4 |
1 |
10 |
1 |
6 |
10 |
11 |
6 |
5 |
1 |
5 |
8 |
12 |
5 |
1 |
7 |
4 |
5 |
9 |
6 |
9 |
2 |
13 |
2 |
4 |
4 |
2 |
3 |
11 |
2 |
2 |
5 |
9 |
3 |
8 |
1 |
10 |
12 |
2 |
8 |
12 |
7 |
9 |
11 |
4 |
1 |
12 |
1 |
4 |
14 |
3 |
13 |
11 |
2 |
7 |
10 |
4 |
1 |
3 |
4 |
12 |
11 |
11 |
11 |
3 |
3 |
4 |
2 |
12 |
11 |
1 |
5 |
9 |
4 |
2 |
1 |
6 |
1 |
12 |
2 |
10 |
5 |
10 |
5 |
1 |
12 |
2 |
14 |
2 |
11 |
7 |
9 |
4 |
11 |
7 |
4 |
4 |
5 |
14 |
12 |
12 |
5 |
2 |
1 |
10 |
12 |
5 |
9 |
2 |
11 |
6 |
1 |
12 |
14 |
3 |
6 |
1 |
14 |
5 |
9 |
11 |
10 |
1 |
4 |
2 |
5 |
12 |
14 |
10 |
10 |
4 |
5 |
8 |
4 |
5 |
6 |
10 |
12 |
4 |
6 |
12 |
5 |
4 |
2 |
1 |
13 |
6 |
8 |
9 |
10 |
10 |
14 |
5 |
3 |
6 |
14 |
10 |
11 |
3 |
3 |
2 |
9 |
10 |
12 |
5 |
7 |
13 |
3 |
7 |
10 |
5 |
12 |
6 |
4 |
1 |
2 |
5 |
13 |
6 |
1 |
13 |
4 |
14 |
13 |
2 |
12 |
1 |
14 |
1 |
9 |
4 |
11 |
13 |
2 |
6 |
10 |
1 |
10 |
7 |
4 |
5 |
8 |
7 |
2 |
2 |
10 |
13 |
4 |
8 |
2 |
11 |
4 |
6 |
14 |
4 |
8 |
2 |
6 |
2 |
3 |
7 |
1 |
12 |
11 |
2 |
9 |
5 |
6 |
10 |
4 |
13 |
4 |
5 |
10 |
4 |
11 |
9 |
3 |
3 |
11 |
9 |
3 |
2 |
3 |
8 |
15 |
6 |
20 |
17 |
19 |
21 |
10 |
15 |
3 |
7 |
11 |
11 |
7 |
17 |
20 |
14 |
9 |
16 |
6 |
17 |
13 |
21 |
21 |
15 |
7 |
17 |
10 |
22 |
22 |
3 |
20 |
8 |
15 |
20 |
16 |
17 |
21 |
10 |
16 |
6 |
22 |
6 |
21 |
14 |
14 |
14 |
16 |
7 |
17 |
3 |
20 |
10 |
7 |
16 |
19 |
14 |
17 |
7 |
21 |
20 |
16 |
7 |
15 |
22 |
10 |
20 |
10 |
18 |
11 |
22 |
18 |
18 |
7 |
19 |
15 |
7 |
22 |
21 |
18 |
7 |
21 |
16 |
3 |
14 |
13 |
7 |
22 |
17 |
13 |
19 |
7 |
8 |
12 |
10 |
17 |
15 |
3 |
21 |
14 |
9 |
7 |
19 |
6 |
15 |
7 |
14 |
14 |
4 |
17 |
10 |
15 |
20 |
19 |
21 |
6 |
18 |
4 |
20 |
16 |
2 |
19 |
8 |
17 |
6 |
13 |
13 |
12 |
6 |
17 |
4 |
20 |
16 |
21 |
12 |
10 |
19 |
16 |
14 |
14 |
15 |
2 |
7 |
21 |
8 |
16 |
21 |
6 |
22 |
16 |
14 |
17 |
22 |
14 |
17 |
20 |
10 |
21 |
7 |
15 |
21 |
18 |
16 |
13 |
20 |
18 |
21 |
12 |
15 |
7 |
4 |
22 |
14 |
13 |
7 |
19 |
14 |
8 |
15 |
4 |
4 |
5 |
3 |
20 |
7 |
16 |
22 |
18 |
6 |
18 |
13 |
20 |
19 |
6 |
16 |
3 |
13 |
3 |
18 |
6 |
22 |
7 |
20 |
18 |
10 |
17 |
11 |
21 |
8 |
13 |
7 |
10 |
17 |
19 |
10 |
14 |
Wherein:
(A) each of 1 to 22 is a 4mer selected from the group of 4mers consisting of WWWW, WWWX, WWWY, WWXW, WWXX, WWXY, WWYW, WWYX, WWYY, WXWW, WXWX, WXWY, WXXW, WXXX, WXXXY, WXYW, WXYX, WXYY, WYWW, WYWX, WYWY, WYXW, WYXX, WYXY, WYYW, WYYX, WYYY, XWWW, XWWW, XWWX, XWWY, XWXW, XWXX, XWXY, XWYW, XWYY, XXWW, XXWX, XXWY, XXXW, XXXX, XXXY, XXYW, XXYX, XXYY, XYWW, XYWX, XYWY, WYXW, XYXX, XYXY, XYYW, XYYX, XYYY, YWWW, YWWX, YWWY,YWXW, YWXX,YWXY, YWYW, YWYX, YWYY, YXWW, YXWX, YXWY, YXXW, YXXX, YXXY, YXYW, YXYX, YXYY, YYWW, YYWX, YYWY, YYXW, YYXX, YYXY, YYYW, YYYX, AND YYYY, AND
(B) each of 1 to 22 is selected so as to be different from all of the others of 1 to 22;
(C) each of W, X, and Y is a base in which:
(i) (a) W=one of A, T/U, G and C
X=one of A, T/U, G and C,
Y=one of A, T/U, G and C,
And each of W, X, and Y is selected so as to be different from all of the others of W, X, and Y,
(b) an unselected said base of (i)(a) can be substituted any number of times for any one of W, X and Y, or
(II)(a)W=G or C,
X=A OR T/U
Y=A OR T/U
AND X-Y AND
(B) a base not selected in (II) (a) can be inserted into each sequence at one or more locations, the location of each insertion being the same in all sequences.
Up to three bases can be inserted at any location of anyof the sequences or up to three bases can be deleted from any of the sequences;
(E) all of the sequences of a said group of oligonucleotides are read 5' to 3' or are read 3' to 5'; and
wherein each oligonucleotide of a said set has a sequence of at least ten contiguous bases of the sequences on which it is based, provided that:
(F)(I) the quotient of the sum of G and C divided by the sum of A, T/U, G and C for all combined sequences of the set is between about 0.1 and 0.40 and said quotient for each sequence of the set does not vary from the quotient for the combined sequences by more than 0.2; and
(II) for any phantom sequence generated from any pair of first and second sequences of the set L1 L2 in length, respectively, by selection from the first and second sequences of identical bases in identical sequences with each other:
(i) any consecutive sequence of bases in the phantom sequence which is identical to a consecutive sequence of bases in each of the first and second sequences from which it is generated is less than ((3/4 x L)-1) bases in length;
(ii) the phantom sequences, if greater than or equal to (5/6xL) in length, contains at least three insertions/deletions or mismatches when compared to the first and second sequences from which it is generated; and
(iii) the phantom sequences is not greater than or equal to (11/12xL) in length;
where L=L1; or L1L=2, where L is the greater of L1 and L2; and
where in any base present may be substituted by an analogue thereof.
We claim:
1. A penetrating peptide comprising at least one amino acid sequence selected from the group consisting of:
a. (BX)4z(BX)2ZXB;
b. ZBXB2XBXB2XBX3BXB2X2B2;
c. ZBZE2B4XB3ZXB4Z2B2;
d. ZB9XBX2B2ZBXZBX2;
e. BZB8XB9X2ZXB
f. B2ZXZB5XB2X2BZB2;
g. XB9XBXB6X3B;
h. X2B3XB4XB9XB;
i. XB2XZBXBZXB2ZXBX3BZXBX3B;
j. BZXBXZX2B4XBX2BXB4X2;
k. BZXBXZX2B4XBX2BXB4;
l. B2XZ2XB4XBX2B5X2B2;
m. BqXTZBMXqB4XBXnBMZB2X2B2;
n. B2ZX3ZBmXqB4XBXNBMZB2X2B2;
o. X3ZB6BZB2X2B2; AND
p. at least 12 contiguous amino acids of any of peptides a) through o)
wherein
q is O or 1;
m is 1 or 2;
n is 2 or 3;
t is 1 or 2 or 3; and
X is any amino acid;
B is hydrophobic amino acid; and
Z is charged amino acid;
wherein said penetrating peptide is capble of translocationg accross a biological barrier.
Production
We Can Not Hire Our Way Out !!!
[D]
Contact Information
John Doll
Commissioner for Patents
e-mail: john.doll@uspto.gov
Phone: 571 272 8250
James Toupin – General Counsel February 1, 2006
Summary of Proposed Rule Changes to Continuations,Double Patenting, and Claims
Continuations/Double Patenting Proposed Rulemaking
- Main objectives:
- Assure adequate opportunity for prosecution to provide appropriate invention protection
- Limit the “recycling” of old applications to permit the USPTO to focus examining resources on “new” applications
- Create greater public certainty on scope of patent protection
- Reduce the burden on the USPTO to review applications for double patenting
Central Provisions on Continuation Practice
- No change for the vast majority of applications
- One continuation (broadly defined) always available as of right, whether in the form of
- continuation application, or a request for continued examination (RCE); but with
- with special rules for divisionals and continuations-in-part (CIPs)
- Additional continuations available if applicant can show that the amendment, argument or evidence could not have been earlier submitted
Divisionals
- Only involuntary divisionals to be permitted:
- Prior application subject to unity of invention (PCT Rule 13) requirement or restriction requirement (35 USC 121); and
- Divisional contains only claims to inventions identified in the requirement and not elected in prior-filed application
- Divisional application may claim the benefit of only a single prior-filed nonprovisional application.
Continuations-in-Part
- Identify what claims are supported by the parent’s disclosure
- Identified claims (which are supported by parent’s disclosure) are given the earlier filing date
- Claims not identified are only entitled to the filing date of the CIP
- A continuation of the CIP is permitted but all claims only entitled to benefit of filing date of CIP
- Practice consequence: Only include “new matter” claims in continuation from CIP
Identification of Related Applications and Double-Patenting
- Identify any other application or patent having:
- Common inventor;
- Common assignee, or those so treated under CREATE Act; and
- Filed within two months (taking into account priority/benefit claims)
- A rebuttable presumption of double-patenting is established for identified applications/patents if have:
- Same effective filing date
- Substantially overlapping disclosure
Double-Patenting: Rebutting the Rebuttable Presumption
- Applicant must:
- Show claims of application are patentably distinct from claims of other patent or application, or
- Submit a terminal disclaimer and explanation of why patentably indistinct claims in two or more such applications should be maintained
- If USPTO finds claims patentably indistinct, it may merge or require cancellation of indistinct claims unless good and sufficient reason shown
Claims Proposed Rulemaking
- Main Purposes
- Applicant Assistance to Improve Focus of Examination
- Narrow scope of initial examination so the examiner is addressing discrete number of issues
- Improve the quality of first Office actions
- Addressing Disproportionate Burdens on Examination System Posed by Applications with Large Numbers of Claims
Central Provisions: Representative Claims
- Normal Pattern: Applicant to identify 10 representative claims for initial examination
- Must include all independent claims
- If independent claims fewer than 10, designate additional dependent claims until total of 10 reached
- Full initial examination of all designated representative claims
- No first action final
Non-Designated Dependent Claims
- If representative claim is allowed, all its non-designated dependent claims will be examined for compliance with 35 USC 101 and 112
- If representative claim is rejected, applicant may, for example:
- Traverse rejection; or
- Amend the claim, including adding subject matter from a non-designated dependent claim; or
- Submit substitute representative claim
Distribution of Independent Claims at Filing
[D]
Beyond 10 Claims: When Initial Examination of 10 Isn’t Enough
- Circumstance should arise rarely
- Circumstance may arise:
- where Applicant needs more than 10 independent claims
- if Applicant cannot prioritize dependent claims so that there are only 10 representative (all independent and designated dependent) claims
Beyond the 10 Claims: Assistance to Examination Document Required
- Applicant must:
- Provide search report of all representative claims
- Identify all limitations of representative claims that are disclosed by cited prior art references
- Explain how all representative claims are patentable over the cited references
Strategic Choices: Before or During Prosecution
- Decision may be made in course of prosecution
-
Applicant may choose additional representative claims after first action. If total available representative claims exceeds 10, examination support document is req’d.
- Rather than provide the support for examination document if there are more than 10 representative claims, applicant may:
- Cancel designated (or independent) claims
- Excess Claim fees paid on/after December 8, 2004 refunded
- Remove designation of dependent claims to bring total representative claims to 10 or less
Comments Appreciated
- Proposed Rules published in January 3, 2006, Federal Register
- Continuations: 71 Fed. Reg. 48
- Claims: 71 Fed. Reg. 61
- 120-day comment period
- Comments due May 3, 2006
-
File by fax, e-mail, mail or Internet
Contact Information
James Toupin
General Counsel
e-mail: james.toupin@uspto.gov
Phone: 571 272 7000
John Doll – Commissioner for Patents
February 1, 2006
Pendency Projections
[D]
Pendency Using FY 2005 Actual Filings at 8.1% Graph
[D]
Pendency Using FY 2005 Actual Filings at 8.1% Graph
[D]
Pendency Using FY 2005 Actual Filings at 8.1% Graph
[D]
Pendency Using FY 2005 Actual Filings at 8.1% Graph
[D]
Stats and Stuff
Total Continuation Filing Rates
[D]
Distribution of Independent Claims at Filing
[D]
Distribution of Total Claims at Filing
[D]
Total Claims at Filing and Issue
[D]
Distribution of the Number of References Cited in Applications
[D]
Changes to Practice for the Examination of
Claims in Patent Applications
Examples
Election of Claims – Example 1
[D]
- All independent claims must be elected.
-
The election of claim 3 is improper. An elected dependent claim must depend from another elected claim. Applicant can choose to re-write claim 3 to depend from 1, or also elect claim 2 to be examined.
Election of Claims – Example 2
Claims
1. An apparatus comprising….
…
…
The method of using the apparatus of claim 1 to …..
Claim 7 is an independent method claim and will be treated as such for the purposes of claim election. Therefore, it must be elected to be examined.
Election of Claims – Example 3
Claims:
1. An apparatus comprising….
…
…
An apparatus as claimed in one of claims 1-3 further comprising….
For the purposes of election, proper multiply dependent claim 4 will be treated as 3 separate claims. Thus, 3 claims will be counted to determine whether the applicant has exceeded the 10 claim limit to avoid submission of an examiner support document.
Election of Claims – Example 4
Applicant files an application with claims to a single invention. The application is filed with 10 total claims: 3 independent claims and 7 dependent claims.
For examination purposes:
- If the applicant designates all 7 dependent claims for initial examination, the Office will give initial examination to all 10 claims.
- If the applicant does not designate any dependent claims for initial examination, the Office will give initial examination only to the 3 independent claims.
Election of claims – Example 5
Applicant files an application with claims to a single invention. The application is filed with 10 total claims: 3 independent claims and 7 dependent claims. The applicant designates all dependent claims, in addition to the independent claims, as representative claims for initial examination.
Applicant files an amendment which (a) cancels 3 claims (1 independent and 2 dependent) and (b) adds 11 claims (4 independent and 7 dependent). The application, as amended, now contains 18 claims: 6 independent claims and 12 dependent claims.
- If the applicant does not change the original designation of dependent claims,*
- the applicant must submit an examination support document covering the 11 representative claims, or
-
reduce the number of representative claims to 10 or fewer by canceling independent claims, rescinding the designating of dependent claims for initial examination, or a combination of thereof.
*In this instance, there are now 11 designated representative claims: 6 independent claims and 5 dependent claims.
Election of claims – Example 6
Applicant files an application with claims to a single invention. The application is filed with 20 total claims: 3 independent claims and 17 dependent claims.
- If applicant does not designate any dependent claims for initial examination, the Office will give initial examination only to the 3 independent claims.
- If applicant designates 7 dependent claims for initial examination, the Office will give initial examination to 10 claims; 3 independent claims and 7 designated dependent claims.
Election of claims – Example 7
Applicant files an application with claims to a single invention. The application is filed with 20 total claims: 3 independent claims and 17 dependent claims.
If applicant designates all 17 dependent claims for initial examination, the application will have 20 representative claims. Applicant must:
- submit an examination support document covering the 20 representative claims, or
-
reduce the number of representative claims to 10 or fewer by canceling independent claims, rescinding the designating of dependent claims for initial examination, or a combination thereof.
Election of claims – Example 8
Example 1: An applicant files an application with claims to 3 distinct inventions. The application is filed with 30 claims: 3 independent claims and 27 dependent claims.
If applicant does not designate any dependent claims for initial examination:
- The Office give initial examination only to the 3 independent claims.
-
The Office may still restrict the application to a single invention
Election of claims – Example 9
An applicant files an application with claims to 3 distinct inventions. The application is filed with 30 claims: 3 independent claims and 27 dependent claims
If the applicant designates 7 dependent claims for initial examination:
- The Office will give initial examination to 10 claims: 3 independent claims and 7 designated dependent claims.
-
The Office may still restrict the application to a single invention.
Election of claims – Example 10
An applicant files an application with claims to 3 distinct inventions. The application is filed with 30 claims: 3 independent claims and 27 dependent claims.
If applicant designates all 27 dependent claims for initial examination, the application will have 30 representative claims. The applicant must:
- submit an examination support document covering the 30 representative claims;
- reduce the number of representative claims to 10 or fewer by canceling independent claims, rescinding the designating of dependent claims for initial examination, or a combination thereof; and/or
- reduce the number of representative claims to 10 or fewer by suggesting a requirement for restriction and election w/out traverse of such representative claims.
Changes to Practice for Continuing Applications
Examples
ContinuationsBenefit Claims under 35 USC 120, 121, or 365(c)
One RCE, Continuation, or CIP Permitted
- Provisional
Application
- Nonprovisional
Application claiming the benefit of the provisional application,
35 USC 119(e)
- Applicant may file:
an RCE, or
a continuation or a CIP application, claiming a benefit under 35 USC 120, 121 or 365(c)
Divisional Applications Can Only Claim Benefit of One Prior Nonprovisional Application That Was Subject to a Restriction or Unity of Invention Requirement
- Nonprovisional
Application with claims to inventions A, B, and C
Restriction made in Application #1 Applicant elected invention A and canceled claims directed to B, and C
- Applicant may file
Divisional Applications claiming only the benefit of application #1 and the claims must be directed non-elected inventions in application #1
- Applicant may file
Divisional Applications claiming only the benefit of application #1 and the claims must be directed non-elected inventions in application #1
One Continuing Filing after a Divisional Permitted
- Provisional
Application
- Nonprovisional
Application claiming the benefit of the provisional application,
35 USC 119(e)
- Divisional Application (as defined in proposed rule) to non-elected invention
- Applicant may file:
a single RCE, or
continuation or CIP application of the divisional application
Second Continuing Filing Requires Petition & Showing That the Amendment, Argument, or Evidence Could Not Have Been Earlier Submitted
- Provisional
Application
- Nonprovisional
Application claiming the benefit of the provisional application
- A first continuing application or an RCE
- Applicant may file a second or subsequent RCE or continuing application w/ a petition and showing
Continuations – Example 1
Scenario: Applicant files application #1 with 65 claims. The USPTO requires restriction between the following groups:
-
Invention 1 - 15 claims; 3 independent + 12 dependent claims
- Invention 2 - 30 claims; 5 independent + 25 dependent claims
- Invention 3 - 20 claims; 1 independent + 19 dependent claims
Applicant may file two divisional applications, one each for inventions 2 and 3.
- But, both will need to be filed during the pendency of application #1 in order to be entitled to claim the benefit of application #1’s filing date. If divisional #3 is filed during the pendency of divisional #2, but not during pendency of application #1, it will only be entitled to the filing date of divisional #2.
Continuations – Example 2
Scenario: Applicant files application #1 claiming only 1 invention. Later, applicant files application #2 with the same disclosure but claims direction to a different invention. In application #2, the applicant claims the priority of application #1’s filing date.
This is permitted, but application #2 will be treated as the one continuation of application #1 allowed as a matter of right.
- Therefore, neither applications #1 or #2 can have any additional RCEs or continuations absent a petition.
- Also, as both applications have the same effective filing date, there will be rebuttable presumption of double patenting. The applicant will need to file a terminal disclaimer or argue persuasively that the claims are patentably distinct.
Examples of a Showing for Filing a Second Continuing Application
Example 1: In a continuation application,
- An interference is declared in an application containing both claims corresponding to the count(s) and claims not corresponding to the count(s), and
- The APJ suggests that the claims not corresponding to the count(s) be canceled from the application in interference and pursued in a separate application.
Example 2: In a continuation application,
- Data necessary to support a showing of unexpected results just became available to overcome a final rejection under 35 U.S.C. 103, and
- The data is the result of a lengthy experimentation that was started after applicant received the rejection for the first time.
Example 3: In a continuation application,
- The final rejection contains a new ground of rejection that could not have been anticipated by the applicant, and
- The applicant seeks to submit evidence which could not have been submitted earlier to overcome this new rejection.
Examples of Unacceptable Showing for Filing a Second Continuing Application
Example 1:
- An argument that a final rejection in one of the prior applications was premature.
- Applicant should address the propriety of the final rejection during prosecution of the prior application, and not collaterally in a petition for a continuation application.
Example 2:
- An argument that an amendment after final rejection should have been entered in the prior application.
- Applicant should address the non-entry in the prior application, and not collaterally in a petition for a continuation application.
To Submit Comments:
Comments should be sent by electronic mail to the following addresses:
Continuations – AB93Comments@uspto.gov
Claims – AB94Comments@uspto.gov
Contact Information
John Doll
Commissioner for Patents
e-mail: john.doll@uspto.gov
Phone: 571 272 8250 |